Sector News

Gilead investing £19.6 million into UK expansion

February 10, 2015
Life sciences
Gilead Sciences is to create new UK commercial headquarters in London and expand its existing operations in the country.
 
The US biotech major is setting up home in Holborn and expanding its international operations in Uxbridge and UK R&D headquarters in Cambridge. The moves represent an increased investment of $19.6 million, doubling Gilead’s UK workforce to 600 by the end of the year – 400 will be based in London.
 
Boston-based Gilead’s investment was announced by Mayor of London Boris Johnson on US trade mission to drum up new business for the capital. The announcement comes less than a year since he launched MedCity, which aims to help the life sciences industry in London and the greater south east of England.
 
Mayor Johnson also announced that another Boston-based company Mobiquity, which specialises in mobile health, is investing £13 million over the next two years in a new London base. He said that Gilead and Mobiquity’s moves to London “further underline the growing importance of the life sciences industry in the UK as we look to ensure that this crucial sector becomes a key contributor to the capital’s growth and health”.
 
In November, Merck & Co announced a £42 million investment to create a new London licensing hub, expand research in Hertfordshire and fund clinical research in oncology and dementia. Pfizer is setting up a new gene therapy unit in the capital focused on rare diseases.
 
By Kevin Grogan
 

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach